|
Shortage Solution Requires Active Industry Collaboration, FDA Says
Drug shortages, poor product quality, poor corrective actions and other “manufacturing breakdowns” have conspired to create a crisis state that demands not only strong regulatory enforcement, but also active collaboration among drugmakers, FDA officials say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives